Outcome of cardiac failure events in the ASPIRE, ENDEAVOR, and FOCUS trials
| . | ASPIRE . | ENDEAVOR . | FOCUS . | |||
|---|---|---|---|---|---|---|
| Carfilzomib (KRd) . | Control (Rd) . | Carfilzomib (Kd) . | Control (Vd) . | Carfilzomib (carfilzomib) . | Control (BSC) . | |
| Patients with cardiac failure, n | 25 | 16 | 38 | 13 | 12 | 7 |
| Any-grade (standardized MedDRA query, narrow scope) cardiac failure outcome, n (%) | ||||||
| Resolved | 15 (60.0) | 6 (37.5) | 14 (36.8) | 8 (61.5) | 6 (50.0) | 1 (14.3) |
| Resolved with sequelae | 2 (8) | 0 | 0 | 0 | 0 | 0 |
| Not resolved | 10 (40) | 10 (62.5) | 23 (60.5) | 5 (38.5) | 6 (50) | 5 (71.4) |
| Deaths | 3 (12.0) | 4 (25.0) | 2 (5.3) | 2 (15.4) | 2 (16.7) | 2 (28.6) |
| . | ASPIRE . | ENDEAVOR . | FOCUS . | |||
|---|---|---|---|---|---|---|
| Carfilzomib (KRd) . | Control (Rd) . | Carfilzomib (Kd) . | Control (Vd) . | Carfilzomib (carfilzomib) . | Control (BSC) . | |
| Patients with cardiac failure, n | 25 | 16 | 38 | 13 | 12 | 7 |
| Any-grade (standardized MedDRA query, narrow scope) cardiac failure outcome, n (%) | ||||||
| Resolved | 15 (60.0) | 6 (37.5) | 14 (36.8) | 8 (61.5) | 6 (50.0) | 1 (14.3) |
| Resolved with sequelae | 2 (8) | 0 | 0 | 0 | 0 | 0 |
| Not resolved | 10 (40) | 10 (62.5) | 23 (60.5) | 5 (38.5) | 6 (50) | 5 (71.4) |
| Deaths | 3 (12.0) | 4 (25.0) | 2 (5.3) | 2 (15.4) | 2 (16.7) | 2 (28.6) |